Arcutis Projects $455-470M ZORYVE Revenue for 2026 as Dermatology Portfolio Expands
Key Insights
Arcutis Biotherapeutics forecasts ZORYVE net product sales of $455-470 million for 2026, representing continued strong growth of the PDE4 (search) inhibitor franchise across multiple inflammatory skin conditions.
The company plans to expand its dermatology sales force by approximately 20% in 2026 to accelerate conversion from topical corticosteroids and deepen ZORYVE adoption among prescribers.
Phase 2 proof-of-concept trials are underway for ZORYVE in vitiligo (search) and hidradenitis suppurativa (search), with program advancement decisions expected in Q4 2026 and Q1 2027 respectively.
Arcutis Biotherapeutics announced ambitious growth projections for 2026, forecasting net product sales of $455-470 million for its flagship ZORYVE franchise while advancing multiple pipeline programs across inflammatory dermatology conditions. The commercial-stage biopharmaceutical company outlined strategic priorities focused on expanding market penetration and clinical development during a corporate update.
ZORYVE Franchise Momentum Continues
ZORYVE, a next-generation phosphodiesterase-4 (search) (PDE4 (search)) inhibitor, has demonstrated remarkable commercial trajectory since its market debut in August 2022. Product revenue grew from $3.7 million in 2022 to approximately $59.6 million in 2023, then accelerated to roughly $166.5 million in 2024. The momentum continued through 2025, with ZORYVE generating $244.6 million in net product revenue in the first nine months alone.
"2025 was a transformative year as we solidified ZORYVE's position as an advanced targeted topical with the potential to redefine the standard of care for chronic inflammatory skin diseases," said Frank Watanabe, president and chief executive officer of Arcutis.
The company projects peak sales of ZORYVE to reach $2.6-3.5 billion, positioning the therapy as a potential blockbuster in the dermatology market. Currently available in cream and foam formulations at multiple strengths, ZORYVE is approved for plaque psoriasis (search), atopic dermatitis (search), and seborrheic dermatitis (search) across various pediatric and adult populations.
Commercial Strategy and Label Expansion
To accelerate growth, Arcutis plans a targeted 20% expansion of its dermatology sales force in 2026 to optimize prescriber targeting and call frequency. The company aims to establish ZORYVE as the foundational therapy for adults and children requiring long-term therapeutic solutions for managing chronic inflammatory skin diseases.
Several regulatory milestones are anticipated in 2026. The FDA is currently reviewing a supplemental New Drug Application (sNDA) for ZORYVE cream 0.3% for treating plaque psoriasis (search) in children ages 2-5, with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026.
Additionally, topline results from the INTEGUMENT-INFANT Phase 2 study of ZORYVE cream 0.05% in infants aged 3 months to less than 24 months are expected in the first quarter of 2026, with sNDA submission planned for the third quarter.
Pipeline Expansion Beyond ZORYVE
Arcutis is pursuing strategic life cycle management of ZORYVE through proof-of-concept studies in additional indications. The company expects to report program advancement decisions for investigational ZORYVE foam 0.3% in vitiligo (search) treatment during the fourth quarter of 2026, and for hidradenitis suppurativa (search) treatment in the first quarter of 2027.
Beyond ZORYVE, the company is advancing ARQ-234, a fusion protein that serves as a potent and highly selective checkpoint agonist of the CD200 receptor (search). This biologic candidate is being developed for atopic dermatitis (search), with Phase 1 patient enrollment expected to begin in the first quarter of 2026. Recent preclinical and clinical studies have validated CD200R (search) as a target in atopic dermatitis, with evidence of durable biologic response even after treatment discontinuation.
Financial Position and Market Performance
As of September 30, 2025, Arcutis maintained cash, cash equivalents, restricted cash, and marketable securities totaling $191.4 million. The company's transition to positive cash flows enables investment in both accelerating ZORYVE franchise growth and advancing pipeline development.
Arcutis shares have nearly doubled in value over the past year, reflecting investor confidence in the ZORYVE franchise's commercial success. The stock has traded in a range of $11.13 to $31.77 over the last 12 months, closing at $30.20 in recent trading.
The company's dermatology development platform and commercial capabilities position it to pursue new opportunities while reinforcing its leadership in medical dermatology drug development and commercialization, according to management.